SAKK 25/14

Eribulin as first-line chemotherapy in advanced breast cancer for patients over 70 years

Previous trials have shown that the active sub-stance eribulin can trigger fewer side effects compared to other chemotherapy drugs, which is why the treatment with eribulin was investigated in this trial.

In this trial we wanted to find out how effective and well tolerated eribulin is in older patients. In this trial, by contrast, eribulin was administered as the first chemotherapy in advanced breast cancer (first-line chemotherapy). Eribulin is already approved in Switzerland for the treatment of advanced breast cancer.

Download
Lay Summaries SAKK 25/14

Further Studies: Breast cancer

SAKK 66/22

Triple-negative (hormone-independent) breast cancer, TNBC

SAKK 23/16 TAXIS

Surgical lymph node removal with the option of “extensive operation” or “radiotherapy” in breast cancer patients with existing axillary lymph node involvement

CAMBRIA-2

A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.

IBCSG 52-15 PALLAS

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

IBCSG 67-22 PREcoopERA

A Window-of-Opportunity trial of giredestrant +/- triptorelin vs. anastrozole + triptorelin in premenopausal patients with ER-positive/HER2-negative early breast cancer.

IBCSG 48-14 POSITIVE

A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy (POSITIVE).

Eribulin as first-line chemotherapy in advanced breast cancer for patients over 70 years

Lay Summaries SAKK 25/14

Further Studies: Breast cancer

Triple-negative (hormone-independent) breast cancer, TNBC

Surgical lymph node removal with the option of “extensive operation” or “radiotherapy” in breast cancer patients with existing axillary lymph node involvement

Researchers are looking for a better way to treat ER+/HER2- early-stage breast cancer

Breast cancer: is surgery still necessary if tumor tissue can no longer be detected following chemotherapy?

Does doxycycline improve breast cancer treatment?

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

A Window-of-Opportunity trial of giredestrant +/- triptorelin vs. anastrozole + triptorelin in premenopausal patients with ER-positive/HER2-negative early breast cancer.

A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy (POSITIVE).